Moderna, Inc. - Award from U.S. Government Agency BARDA to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Moderna's conference call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Lavina Talukdar. Please go ahead, ma'am.
Thank you, operator. Good morning, and welcome to Moderna's conference call. Today, we will discuss the award from the Biomedical Advanced Research and Development Authority, or BARDA, to accelerate the development of mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued yesterday evening by going to the Investors section of our website.
Today on this call, we have Stéphane Bancel, Chief Executive Officer; Stephen Hoge, President; Tal Zaks, Chief Medical Officer; Juan Andres, Chief Technical Operations and Quality Officer; and Lorence Kim, Chief Financial Officer.
Before we begin, please note that this conference call will include forward-looking statements. Please see our SEC filings for important risk factors that could
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |